LONDON, Nov 7 — Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

Novo Nordisk has announced that its experimental obesity drug, CagriSema, is showing side effects similar to existing GLP-1 drugs. The company expects the new drug to deliver a 25% weight loss. Novo ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 ...